Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantation

Publisher Website
Google Scholar
Abstract
In 1991, the United States Food and Drug Administration (FDA) approved the commercial sale of colony-stimulating factors for use in cancer patients receiving cytotoxic agent therapy. Many of the data to support the licensure of the two approved agents, G-CSF (filgrastim) and GM-CSF (sargramostim), were derived from studies conducted in patients undergoing bone marrow transplantation. This group of agents, predominantly glycoproteins in nature, controls the survival, proliferation, and differentiation of the various hematopoietic blood cell lineages [1–5]. These agents act on both early and committed progenitors and enhance the function of mature effector cells [6].